IFA
12.9.2019 11:59:07 CEST | Business Wire | Press release
IFA Berlin has turned out to be another huge success story with nearly 2,000 exhibitors, 245,000 visitors, and a new all-time high for international attendance, with more than 50 percent of trade visitors coming from abroad. Three big technology trends dominated IFA across both consumer electronics and home appliances: voice, artificial intelligence and connectivity, especially given the rapid roll-out of high-speed, high bandwidth 5G mobile networks.
Two IFA Keynotes – by Huawei CEO Richard Yu and Qualcomm President Cristiano Amon - focused on how 5G-connectivity can push the power of artificial intelligence to the very edge of computing – in the devices, into vehicles and into industrial applications.
Anthony Wood , the CEO of Roku – which powers one third of all set-top boxes in the United States – used his keynote to outline his vision of how online streaming will dominate the TV experience, and announced his company’s expansion to the UK, with plans to move to other European countries as well. Hakan Bulgurlu , the CEO of Arçelik, dedicated his keynote to demanding industry action against climate change and plastic waste.
IFA’s innovation hub – IFA NEXT – also set new records with more start-ups and innovation leaders than ever spread across two halls, alongside research institutes from countries like Germany, Japan and Korea. This year, IFA NEXT hosted Japan as its first Global Innovation Partner country; the Japan pavilion was showcasing the newest ideas and innovations for how machines and humans can interact.
Keita Nishiyama , Director General of Commerce and Information Policy - Bureau, Ministry of Economy, Trade and Industry says "We hope that Japan’s Interface with Consideration and Sensibility has inspired IFA visitors to embrace the future and continue on the path of innovation. As the first partner country of IFA NEXT - we look forward to staying in touch with you. Please follow us as Ninja does!”
Once again, IFA Berlin lived up to its reputation as the world’s most important trade show for consumer electronics and home appliance.
"As an important driving force for trade and industry and the world's most important platform for consumer electronics and home appliances, IFA 2019 met the high expectations. With its large number of innovations, it has a positive influence on the mood in the international markets. With an unexpectedly stable high order volume in regard to the current market situation, the foundation was laid for a successful year-end business," explains Hans-Joachim Kamp , Chairman of the Supervisory Board of IFA organizer gfu Consumer & Home Electronics.
"We are satisfied with the results of IFA 2019. Accordingly, the household appliance industry is optimistic about the future. This year too, IFA has strengthened its position as the world's significant trade show for home appliances and made a positive contribution to the market development," states Dr. Reinhard Zinkann , Chairman of the ZVEI.
The CEO of Messe Berlin, Dr. Christian Göke says IFA had once again shown the "power of co-innovation, where inventors in different sectors and industries inspire each other." He warned that trade wars, trade barriers and political barriers would harm consumers not just by making products more expensive, but by slowing down innovation itself. Picking up a theme developed in one of IFA’s most famous keynotes, by Albert Einstein in 1930, Dr. Göke said that in today’s day and age Einstein would probably "call on the best and the brightest minds in the world, whoever they are, and wherever they live, whichever country they call their home, to pool their knowledge and co-innovate to create a better world."
IFA Executive Director Jens Heithecker was hugely impressed by the level of innovation: "As the number of exhibitors has grown, so did the quality and quantity of innovations as well as the number of product premieres that were shown here in Berlin for the first time."
Global media attendance has gone up yet again; the journalists coming to Berlin work for media organisations covering 160 countries around the world. This shows how important IFA is in the calendar for technology and lifestyle journalists. This year, IFA attracted some 2.800 international journalists from around the world.
Among the broadcasters reporting from IFA Berlin were Al Jazeera from the Arab Emirates, NDTV from India, Nine Network from Australia, the BBC from the United Kingdom, IBA International from Israel, TEKNAVI from Finland, CNBC from the USA, CGTN / CCTV, Global Times as well as the Phoenix Group from China. From France teams from Eurosport, 01net TV, LCI, BFM TV, OUATCH.tv, France 24 and ES 1 reported on the latest IFA news. News agencies such as AP and Reuters were represented, alongside public broadcasters working through the EBU and private broadcasters cooperating through ENEX.
SHIFT – Future of Mobility
SHIFT, the two-day convention on how new technologies are shaping the Future of Mobility, has grown strongly compared to the previous year; among the speakers were top executives from industry giants such as AXA insurance, BMW, Daimler/Smart, Ford Fujitsu and Volkswagen, start-ups like 2Getthere, Iomob, LISNR, Trafi, Vive La Car, what3words and Wundermobility, and mobility pioneers like Zipcar Founder Robin Chase, the former CTO of Barcelona Francesca Bria, former Tata Motors CEO Venkat Sumantran, and a very unusual automotive consultant, Jay Ward the creative director of the Cars Franchise at Pixar Animation Studios.
IFA Global Markets
IFA Global Markets exclusively accessible to trade visitors, suppliers, manufacturers and OEMs / ODMs established itself as a significant part of IFA.
Dirk Koslowski
, IFA Director, states: "IFA Global Markets has been growing continuously for four years now. It is thus the leading platform in Europe for the supplier industry and has firmly established its position as the largest sourcing show in Europe."
Covering 20,000 square meters, the B2B marketplace IFA Global Markets was once again fully booked.
IFA Global Events – Save the Dates
CE China 2019
19 - 21 September, Guangzhou, China
CE Week 2020
10 - 11 June, New York, USA
IFA Global Press Conference 2020
2 - 5 April, Cyprus
IFA 2020
4 - 9 September
2 - 3 September, IFA Media Days
2 September, IFA Opening Press Conference, 1 p.m.
6 - 9 September IFA Global Markets
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005397/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom